EDAP Partners with Leading US HIFU provider, Vituro Health Adds Ablatherm Robotic HIFU
August 31 2017 - 1:01PM
Dr. S. Scionti, Medical Director of Vituro and
most experienced HIFU urologist in the U.S. to start treating with
Ablatherm in September
LYON, France, August 31, 2017 -- EDAP TMS SA
(Nasdaq:EDAP), the global leader in therapeutic ultrasound, today
announced that the Company signed a partnership agreement with
Vituro Health LLC, an Alabama-based organization providing HIFU
therapy nationwide to patients with prostate cancer. Vituro Health
has been offering HIFU Sonablate technology to its patients for
years and has decided to add Ablatherm-HIFU to its portfolio to
enlarge its offering. Ablatherm will be made available to Vituro
Health physicians in their training facility in Sarasota, Florida
or on a mobile basis, hence offering the opportunity to access
Ablatherm-HIFU technology on demand.
Dr. Stephen Scionti, Medical Director at Vituro
Health and Founder and Director of The Scionti Prostate Center in
Sarasota, FL, commented: "I am excited to partner with EDAP and
expand our offering using their technology. EDAP's technology
has been the most widely used in the world and we will now have all
FDA approved HIFU technologies available to treat our
patients".
Clete Walker, Chief Executive Officer of Vituro
Health, added: "Expanding our offering to include EDAP's technology
allows us to offer our partners more value and enhances our
precision prostate program. Additionally, adding EDAP to our
industry leading training program allows us to ensure physicians
are properly trained before they perform cases on qualified
patients."
Marc Oczachowski, Chief Executive Officer of
EDAP TMS, commented: "We are extremely proud to partner with Vituro
Health, and bring our Ablatherm-HIFU Robotic technology into their
center of excellence site in Sarasota Florida, The Scionti Prostate
Center. This is going to be a great National and International
reference center for EDAP's unique and superior HIFU
technology."
Oczachowski added: "EDAP is honored by Dr.
Stephen Scionti's choice to incorporate our Ablatherm HIFU device
in his practice. Dr. Scionti is by far the most experienced HIFU
urologist in the US and has performed more than a thousand
treatments over more than a decade. We are looking forward to
assisting his training program and first cases in September under
the proctorship of the most experienced HIFU user in the world,
Prof Stefan Thueroff from Munich, Germany".
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for
high-intensity focused ultrasound (HIFU) for prostate tissue
ablation in the U.S. and for treatment of localized prostate cancer
in the rest of the world. HIFU treatment is shown to be a minimally
invasive and effective option for prostatic tissue ablation with a
low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Ablatherm-HIFU is approved for commercial distribution
in Europe and some other countries including Mexico and Canada, and
has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is
not FDA cleared yet. The Company also markets an innovative
robot-assisted HIFU device, the Focal One®, dedicated to focal
therapy of prostate cancer. Focal One® is CE marked but is not FDA
cleared. The Company also develops its HIFU technology for the
potential treatment of certain other types of tumors. EDAP TMS SA
also produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com ,
and http://www.hifu-prostate.com.
About Vituro Health
Vituro Health empowers men with comprehensive
prostate care during all stages of their lives. We arm partner
physicians with HIFU (high intensity focused ultrasound) technology
and other patient-centric, concierge services to elevate the
standard of care and patient experiences. Vituro Health serves
patients nationwide and is headquartered in Birmingham, Ala.,
with partnering physicians in Birmingham, Sarasota,
Fla., Jacksonville, Fla., Atlanta, Philadelphia, Pa.
the Washington metropolitan area, Dallas,
Tex., Las Vegas, Nev., and Phoenix, Ariz., who are
carefully selected based on their depth of experience, expertise
and dedication to achieving the highest levels of patient outcomes.
For more information and to learn about our physicians,
visit www.viturohealth.com.
Forward-Looking Statements
In addition to historical information, this
press release may contain forward-looking statements. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties, including matters
not yet known to us or not currently considered material by us, and
there can be no assurance that anticipated events will occur or
that the objectives set out will actually be achieved. Important
factors that could cause actual results to differ materially from
the results anticipated in the forward-looking statements include,
among others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
Investor Contact
CG CAPITAL Rich Cockrell 877.889.1972
investorrelations@cg.capital
Company ContactBlandine ConfortInvestor Relations / Legal
Affairs EDAP TMS SA+33 4 72 15 31 50bconfort@edap-tms.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Sep 2023 to Sep 2024